

ARCHIMED VILLE - Prevention of venous thromboembolic events with Arixtra 2.5mg for medical ill patients in general practice

Head :Leclerc-Zwirn Christel, Laboratoire GSK

Last update : 01/01/2020 | Version : 1 | ID : 142

General	
Identification	
Detailed name	Prevention of venous thromboembolic events with Arixtra 2.5mg for medical ill patients in general practice
Sign or acronym	ARCHIMED VILLE
CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation	CNIL : 906318
General Aspects	
Medical area	General practice
Others (details)	venous thromboembolic events
Keywords	pharmaco-epidemiology, thrombosis, fondaparinux, arixtra
Scientific investigator(s) (Contact)	
Name of the director	Leclerc-Zwirn
Surname	Christel
Phone	+33 (0)1 39 17 86 96
Email	christel.c.leclerc-zwirn@gsk.com
Unit	Laboratoire GSK
Collaborations	
Funding	
Funding status	Private
Details	GSK laboratory

Governance of the database	
Sponsor(s) or organisation(s) responsible	LABORATOIRE GSK
Organisation status	Private
Additional contact	
Main features	
Type of database	
Type of database	Study databases
Study databases (details)	Longitudinal study (except cohorts)
Database recruitment is carried out by an intermediary	A selection of health care professionals
Database recruitment is made on the basis of:	Medication(s) taken
Database recruitment is carried out as part of an interventional study	No
Additional information regarding sample selection.	Investigators will be selected via random drawing using a complete sampling frame of the general practitioners exercising in metropolitan France. He will complete a specific inclusion questionnaire for the first 3 patients that meet the eligibility criteria.
Database objective	
Main objective	Evaluate the average duration of treatment via ARIXTRA® 2.5 mg with thromboprophylaxis in ambulatory general practice
Inclusion criteria	Patient of at least 18 years of age, -bedridden or with reduced mobility, -for whom a treatment via ARIXTRA® 2.5 mg is initiated with thromboprophylaxis.
Population type	
Age	Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years) Great age (80 years and more)

Population covered	Sick population
Gender	Male Woman
Geography area	National
Detail of the geography area	France
Data collection	
Dates	
Date of first collection (YYYY or MM/YYYY)	2007
Date of last collection (YYYY or MM/YYYY)	2010
Size of the database	
Size of the database (number of individuals)	[500-1000[individuals
Details of the number of individuals	834
Data	
Database activity	Data collection completed
Type of data collected	Clinical data Declarative data
Clinical data (detail)	Medical registration
Declarative data (detail)	Face to face interview
Presence of a biobank	No
Health parameters studied	Health care consumption and services
Care consumption (detail)	Medicines consumption
Procedures	
Data collection method	Throughout the entire duration of the study, the doctor will log the prescriptions of ARIXTRA® 2,.5 mg for thromboprophylaxis in a registry. This registry will make it possible to evaluate prescription volume and the representativeness of the patients effectively included in the study. The doctor will

complete for each patient included a follow-up questionnaire at the end of treatment.

Participant monitoring Yes

Details on monitoring of participants The data that will be collected in the follow-up questionnaire are: ? Premature interruption of the treatment, ? total duration of the administration of the treatment, ? prescriptions for prophylactic purposes after the treatment.

Links to administrative sources No

Promotion and access

Promotion

Access

Terms of data access (charter for data provision, format of data, availability delay) Publications in progress

Access to aggregated data Access on specific project only

Access to individual data Access on specific project only